Differential binding properties of oripavines at cloned mu- and delta-opioid receptors
- PMID: 10493109
- DOI: 10.1016/s0014-2999(99)00460-4
Differential binding properties of oripavines at cloned mu- and delta-opioid receptors
Abstract
This study examines the possibility that oripavine opioid receptor agonists bind equally to both high and low affinity states of the mu-opioid receptor. Studies were performed in C6 cells expressing mu- or delta-opioid receptors; high and low agonist affinity states of the receptors were defined by the absence and presence, respectively of Na+ ions and the GTP analog Gpp(NH)p. At the mu-opioid receptor dihydroetorphine and etorphine were full agonists, buprenorphine had moderate efficacy while diprenorphine was an antagonist. At the delta-opioid receptor, dihydroetorphine, etorphine, and diprenorphine had moderate efficacy while buprenorphine was an antagonist. The binding affinities of the oripavines at the mu-opioid receptor decreased only one to 2-fold in the presence of NaCl and Gpp(NH)p. In contrast, decreases in oripavine affinity at the delta-opioid receptor correlated with delta-opioid receptor efficacy. The ability of oripavine agonists to bind with high affinity to the low agonist affinity state of the nu-opioid receptor may explain the high potencies of these compounds in vivo.
Similar articles
-
SoRI 9409, a non-peptide opioid mu receptor agonist/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors.Brain Res Bull. 2001 Jul 1;55(4):507-11. doi: 10.1016/s0361-9230(01)00550-0. Brain Res Bull. 2001. PMID: 11543951
-
In vivo opiate receptor binding of oripavines to mu, delta and kappa sites in rat brain as determined by an ex vivo labeling method.Eur J Pharmacol. 1985 Aug 27;114(3):343-53. doi: 10.1016/0014-2999(85)90379-6. Eur J Pharmacol. 1985. PMID: 2998812
-
Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.Mol Pharmacol. 1995 Apr;47(4):848-54. Mol Pharmacol. 1995. PMID: 7723747
-
Pharmacological characterization of human kappa/mu opioid receptor chimeras that retain high affinity for dynorphin A.Curr Top Med Chem. 2005;5(3):303-13. doi: 10.2174/1568026053544542. Curr Top Med Chem. 2005. PMID: 15857313 Review.
-
The orvinols and related opioids--high affinity ligands with diverse efficacy profiles.Curr Pharm Des. 2004;10(7):717-32. doi: 10.2174/1381612043453027. Curr Pharm Des. 2004. PMID: 15032698 Review.
Cited by
-
Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models.Chem Biol Drug Des. 2012 Nov;80(5):763-70. doi: 10.1111/cbdd.12014. Epub 2012 Sep 12. Chem Biol Drug Des. 2012. PMID: 22882801 Free PMC article.
-
Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence.Br J Pharmacol. 2005 Aug;145(7):975-83. doi: 10.1038/sj.bjp.0706247. Br J Pharmacol. 2005. PMID: 15912139 Free PMC article.
-
A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine.J Pharmacol Exp Ther. 2014 Feb;348(2):217-26. doi: 10.1124/jpet.113.209478. Epub 2013 Nov 13. J Pharmacol Exp Ther. 2014. PMID: 24227768 Free PMC article. Clinical Trial.
-
Managing severe cancer pain: the role of transdermal buprenorphine: a systematic review.Ther Clin Risk Manag. 2009 Oct;5(5):707-18. doi: 10.2147/tcrm.s4603. Epub 2009 Sep 15. Ther Clin Risk Manag. 2009. PMID: 19774212 Free PMC article.
-
Post-herpetic neuralgia in older adults: evidence-based approaches to clinical management.Drugs Aging. 2007;24(1):1-19. doi: 10.2165/00002512-200724010-00001. Drugs Aging. 2007. PMID: 17233544 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials